Coercive Control and Intimate Partner Violence (CCVCS)

Coercive Control and Intimate Partner Violence: Examining the Relationships Between Exposure to Violence and Victims' Physical and Mental Health Outcomes

Coercive control (CC) is increasingly recognized as a central component of intimate partner violence (IPV) and a major determinant of victims' health outcomes. While widely integrated into policy and legal frameworks in several countries, CC remains insufficiently explored in the French research context, particularly regarding its clinical and psychopathological dimensions. This gap may limit the identification of victims and the provision of appropriate care.

The present study aims to investigate the association between exposure to coercive control and physical and mental health outcomes among victims of intimate partner violence. By improving the understanding of CC-related health impacts, this research seeks to support better identification of high-risk situations and inform clinical and public health interventions.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Île-de-France Region
      • Aulnay-sous-Bois, Île-de-France Region, France, 93600
        • CHI Robert Ballanger
        • Contact:
        • Principal Investigator:
          • Fatima Le Griguer, psychologist

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Women aged 18 years and older, who have experienced an intimate partner relationship involving violence for at least three months (currently in the relationship or separated).
  • Women identified as victims of intimate partner violence.
  • Sufficient proficiency in French to complete self-administered questionnaires and participate in interviews.
  • No objection to participation in the study (non-opposition).
  • Affiliation with a French social security scheme or eligibility for universal health coverage (Couverture Maladie Universelle, CMU).

Exclusion Criteria:

  • Individuals under legal protection in accordance with the French Public Health Code (Articles L.1121-5 to L.1121-8 and L.1122-1-2), with the exception of pregnant or breastfeeding women.
  • Cognitive impairment or severe intellectual disability preventing comprehension of the questionnaires.
  • Severe and unstable psychiatric disorders (e.g., schizophrenia, delusional disorders, acute bipolar disorder).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Questionnaire arm
Participants will complete online questionnaires via the Qualtrics platform
Participants will complete online questionnaires via the Qualtrics platform at baseline and at 6 months post-enrollment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Coercive Control Screening Scale
Time Frame: Measure of CCSS between inlusion and month 6
Measure of Coercive Control Screening Scale (CCSS). Minimal scale = 0, maximal scale = 44. Higher score means worse outcome
Measure of CCSS between inlusion and month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure of Hospital Anxiety and Depression scale (HAD scale)
Time Frame: Measure of HHAD scale between inclusion and month 6
correlation between HAD scale and CCSS scale. Minimal scale = 0, maximal scale = 42. Higher score means worse outcome
Measure of HHAD scale between inclusion and month 6
Severity of post-traumatic stress disorder symptoms
Time Frame: at inclusion and month 6
Severity of post-traumatic stress disorder (PTSD) symptoms assessed by the PTSD Checklist for DSM-5 (PCL-5), based on total score and DSM-5 clinical thresholds. Minimal scale = 0, maximal scale = 80. Higher score means worse outcome
at inclusion and month 6
International Trauma Questionnaire (ITQ).
Time Frame: Inclusion and month 6
International Trauma Questionnaire (ITQ), according to ICD-11 criteria. Minimal scale = 0, maximal scale = 72. Higher score means worse outcome
Inclusion and month 6
Severity of emotional dysregulation
Time Frame: inclusion and month 6
Severity of emotional dysregulation assessed using the Difficulties in Emotion Regulation Scale - French version (DERS-F). Minimal scale = 36, maximal scale = 180. Higher score means worse outcome
inclusion and month 6
Short Form Health Survey (SF-12)
Time Frame: inclusion and month 6
Health-related quality of life assessed using the 12-Item Short Form Health Survey (SF-12), including physical and mental component summary scores. optimal scale more than 40. scale < 40 means worse outcome
inclusion and month 6
Brief Pain Inventory
Time Frame: at inclusion and month 6
Pain intensity and functional impact assessed using the Brief Pain Inventory (BPI). mninimal scale = 0, maximal scale = 10. Higher score means worse outcome
at inclusion and month 6
Coercive Control Scale (CCSS)
Time Frame: inclusion and month 6
Analysis of score distribution on the Coercive Control Scale (CCSS) to determine a clinically relevant threshold for coercive control. Minimal scale = 0, maximal scale = 44. Higher score means worse outcome
inclusion and month 6
Woman Abuse Screening Tool (WAST)
Time Frame: inclusion and month 6
Intimate partner violence assessed using the Woman Abuse Screening Tool (WAST). minimal scale = 0, maximal scale = 16. Higher score means worse outcome
inclusion and month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: fatima F Le Griguer, psychologist, CHI Robert Balanger of GHT GPNE

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 30, 2026

Primary Completion (Estimated)

May 30, 2028

Study Completion (Estimated)

May 30, 2028

Study Registration Dates

First Submitted

May 5, 2026

First Submitted That Met QC Criteria

May 5, 2026

First Posted (Actual)

May 11, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coercive Control

Clinical Trials on questionnaire

Subscribe